Want to see RMTG full AI Analyst Report?
RMTG Stock Chart & Stats
$0.02
>-$0.01(-26.32%)
At close: 4:00 PM EST
$0.02
>-$0.01(-26.32%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume89.42K
Average Volume (3M)8.37K
Market Cap
$387.60K
Enterprise Value$20.06M
Total Cash (Recent Filing)$1.06M
Total Debt (Recent Filing)$20.58M
Price to Earnings (P/E)―
Beta-0.81
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,138,968
10 Day Avg. Volume641
30 Day Avg. Volume8,365
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.12
P/FCF Ratio-0.47
Enterprise Value/Market Cap51.75
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda17.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high revenue growth indicates expanding market traction and product adoption, creating a base for operating leverage. Over 2-6 months this growth can support scale benefits if management controls SG&A and converts top-line gains into improving operating margins and cash generation.
Healthy Gross MarginA ~57% gross margin signals attractive unit economics and pricing power for core products or services. This structural margin cushion gives the company room to absorb SG&A or R&D while pursuing growth, improving the odds of reaching sustainable operating profitability if fixed costs are managed.
EBITDA ImprovementA move to slightly positive EBITDA shows operational progress and emerging cost discipline, reflecting better conversion of gross profit to operating cash. This durable improvement suggests the business model can attain break-even at scale and reduces the magnitude of ongoing external funding needs.
Bears Say
Negative Equity & LeveragePersistently negative equity and sizable debt relative to a small asset base materially constrain financial flexibility. Over the medium term this raises refinancing and dilution risk, limits ability to invest organically, and makes the company vulnerable to creditor actions or costly capital raises.
Very Large Net LossesExtremely wide negative net margins show that non-operating or operating expenses dwarf gross profit. Such structural losses impair retained capital and require consistent external funding; absent durable cost reductions, losses undermine long-term viability despite revenue growth.
Negative Operating & Free Cash FlowOngoing negative operating and free cash flow mean the business does not self-fund growth and will need external capital. Over a 2-6 month horizon this creates execution risk, potential dilution, and pressure on liquidity, particularly given the stressed balance sheet and outstanding debt.
Regenerative Medical Technology Group News
RMTG FAQ
What was Regenerative Medical Technology Group’s price range in the past 12 months?
Regenerative Medical Technology Group lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
What is Regenerative Medical Technology Group’s market cap?
Regenerative Medical Technology Group’s market cap is $387.60K.
When is Regenerative Medical Technology Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regenerative Medical Technology Group’s earnings last quarter?
Currently, no data Available
Is Regenerative Medical Technology Group overvalued?
According to Wall Street analysts Regenerative Medical Technology Group’s price is currently Overvalued.
Does Regenerative Medical Technology Group pay dividends?
Regenerative Medical Technology Group does not currently pay dividends.
What is Regenerative Medical Technology Group’s EPS estimate?
Regenerative Medical Technology Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regenerative Medical Technology Group have?
Regenerative Medical Technology Group has 13,138,968 shares outstanding.
What happened to Regenerative Medical Technology Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regenerative Medical Technology Group?
Currently, no hedge funds are holding shares in RMTG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Regenerative Medical Technology Group
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Technical Analysis
Bone Biologics
―
INVO Fertility
―
Bluejay Diagnostics
―
NewGenIvf Group
―
WORK Medical Technology Group LTD
―